Cite
HARVARD Citation
Pauligk, C. et al. (n.d.). 36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. European journal of cancer. 51 (3), pp. S728-. [Online].